INTRODUCTION
Variation in foot and mouth disease (FMD) viruses can be demonstrated in numerous ways, and it is useful to examine the impact that variation of FMD viruses can have on the production and use of FMD vaccines.
First, of course, the existence of seven distinct serotypes which lack any degree of cross-protection is itself the result of extreme genetic variation on the part of the FMD virus, and this has necessitated the development of poly valent vaccines. Fortunately, until now it has not been necessary anywhere in the world to include more than four serotypes in a routine production vaccine.
Second, the amount of antigenic variation that occurs within a serotype has demanded that a far greater number of antigenically distinct strains have been used for the production of FMD vaccines over the years than have been required in the production of vaccines against any other disease. To give some idea of the scale of the problem, during the past 10 years within the Wellcome Group alone a total of 45 different strains have been used for com mercial FMD vaccine production and, of course, many others have been eva luated as potential vaccine viruses. During the course of these activities we have found four main areas within which effects associated with variation have had an impact on either the production or the use of FMD vaccines. These are :
1. Preparation of a vaccine seed virus from a field virus. 2. Interpretation of serological data. 3. Antigenic variation affecting either the vaccine virus or the challenge virus used for potency testing. 4 . Antigenic variation of a field virus.
I. -THE PREPARATION OF VACCINE SEED VIRUSES
Genetic variation of FMD virus strains has been described as a result of sequential passaging in almost all the commonly recognised susceptible cell systems, e.g. partially immune cattle, 'carrier' cattle, susceptible cattle during the course of an epizootic, Frenkel cultures, BHK cell cultures, bovine kidney cell cultures, suckling mice, embryonated eggs, suckling rabbits, etc.
The marked genetic lability has been used to advantage in the preparation of live modified vaccines. Although detailed studies using modern viral gene tics techniques have not been made of live modified FMD vaccine strains, it seems likely that prolonged passage and adaptation to normally insusceptible cell systems resulted in a series of small step mutations accompanied by on going selection processes. Probable examples of this are shown by the ability to adapt viruses sequentially to adult mice of increasing age. Adaptation to the new host was usually accompanied by increased cytopathogenicity for that host and was often associated with changes in cell tropism within the susceptible target species.
However, the borderline between loss of virulence for the target species and the continued ability to replicate within that species was extremely nar row with some live modified strains, and it was clear that no one passaging regimen could guarantee achieving a successful degree of attenuation. Like wise, no one genetic marker has been shown to be either positively or negati vely associated with virulence in a susceptible target species.
It is of interest that, although the preparation of a number of live modi fied strains sometimes involved some hundreds of passages in the alternative host cell, no evidence of a major antigenic change was ever reported.
In the production of inactivated vaccines, variation can be encountered during the adaptation of a virus to a cell culture system. Subsequent variation in a vaccine seed virus can be avoided by the operation of the virus seed lot system. However, in the case of Frenkel culture viruses this is not practicable and variation has been reported after the continuous passage that is inherent in the system. Adaptation of a virus strain from BHK monolayer cell culture to BHK suspension cell culture has been associated with variation. Cowan et al. (1974) Although variation appears to be a common sequel during the course of adapting field viruses to BHK cells, particularly suspension-adapted BHK cells, loss of immunogenicity as a result of antigenic variation has not been a problem we have encountered. Equally, although field virus strains which are difficult to adapt to suspension BHK cells are met from time to time, this has never constituted a serious problem within Wellcome Group Laboratories and it would appear that the experience of other laboratories is not dissimi lar. It is of interest to note that sometimes variation during the course of an epizootic will render some field isolates more easily adapted to suspension BHK cells than others, so we prefer to start with as many different isolates of the same candidate vaccine strain as possible.
II. -INTERPRETATION OF SEROLOGICAL DATA
In order to understand more fully the implications involved, it is of inte rest to trace the evolution over, say, the last fifteen years of the criteria used for the serological comparison of a field virus with a vaccine strain. Origi nally, the complement fixation (CF) test was the only system used by the various national and international laboratories for the serological examina tion and classification of field viruses. Although most workers would agree that the CF test was not entirely suitable for making judgements on the appropriateness of a particular vaccine virus for use against a particular field virus which had been shown to be serologically different from it, in the absence of alternative and more meaningful information, they would fre quently end up by trying to do just that. With the added benefit of hindsight, one can look back and identify the specific reasons why the CF test and the criteria relevant for subtyping for classification purposes were not ideally sui ted to matching of vaccine strains with field viruses.
1.
Decisions on vaccine strain suitability were frequently required to be made long before a full subtyping of a field virus had been made. In such cases it was the practice to carry out one-way tests, comparing the field virus against a range of sera prepared from subtype prototype viruses. This produ ced a profile which is quite characteristic for a particular virus and allowed viruses to be identified as being probably the same or probably different. However, the V values calculated in this way (i.e. one virus against several sera) had no biological significance, as it was not possible to distinguish bet ween quantitative effects related to serum titre and to qualitative effects resulting from serum specificity. The phenomenon of unilateral differences between viruses and the related concept of dominance described by Stellmann et al. (1972) did not receive general acceptance in a number of laboratories for many years.
2.
When the full two-way antigenic relationships had been established, a field virus would be allocated either to an existing subtype or would form the prototype for a new subtype.
Whether we adopt the values of 'R' <70% (Brooksby, 1968) , or 'R' <25% (Forman, 1975) or of both 'r1' and 'r 2 ' being <0.25 (Pereira, 1977) as the threshold for subtype differentiation, it has to be accepted that such values obtained using the CF test are quite arbitrary in that they are not cor related with any quantifiable cross-protection relationship. It was always well recognized that viruses showing subtype differences based on the 70% dis tinction level did not offer good cross-protection (Hyslop and Fagg, 1963). However, unfortunately the corollary to this concept, although perhaps it was never stated as such, was that it became to be generally expected that strains which did not show subtype degrees of difference were for all practi cal purposes identical and would therefore cross protect well. It was only later that the concept of subtypes forming discontinuous groups of very clo sely related viruses was moved away from (Forman, 1975 ).
3.
The work of Brown and Smale (1970) and Cowan (1973) made it clear that the neutralization reaction was concerned only with the trypsin-sensitive polypeptide, whereas the CF test does not discriminate between the different surface antigens of the FMD virion. Serological examination of pairs of viru ses showed that in 25% of cases the V value calculated from SN test values was more than four-fold lower than that calculated from CF test data (Rweyemamu et al., 1977a) . This is not surprising in so far as it seems likely that a system which measures only the one antigen in which we are interested is capable of showing a greater degree of difference than a system which simultaneously measures both this antigen and other antigens which may be common to both viruses.
Ubertini and his colleagues (1964) showed that the neutralization test was capable of detecting serological variations which could be related to crossprotection differences among type A field isolates which were all classifiable within the same subtype by CF test data. Unfortunately, the full significance of this most important observation was not appreciated by the national and international FMD laboratories and, although I first went on record as a pro tagonist of the neutralization test for virus strain evaluation at the FMD Mee ting of the International Association of Biological Standardisation (IABS) in 1967 (Pay, 1968), it was not until the next FMD meeting of IABS in 1976 that in a presentation from our laboratory (Rweyemamu et al., 1977a) we put for ward the view that the criteria for vaccine strain evaluation, although related, are quite distinct from those used for classification. We formulated the con cepts that :
a) The neutralization test should be the serological method of choice. b) Antisera to vaccine viruses should form the basis for comparison.
c) The 'r' value should form the basis of strain selection. d) Test errors should be considered in arriving at the significance of a 'r' value. More recently a joint proposal from AVRI and Wellcome embracing these concepts was endorsed by the FMD Vaccine Strains Committee of IABS in May, 1981.
It is against this background that we may now identify examples of some of the problems we have encountered over the years. Wellcome Foundation Limited was in a position to supply bottled vaccine ex stock against any of these three subtypes, but on the strength of the neu tralization test data we felt that, while we could strongly advise the use of the A 24 Cruzeiro vaccine, we could under no circumstances recommended the use of the A 22 or A 5 vaccines.
5. An example of the importance of working with an antiserum prepared from the vaccine virus in preference to an antiserum against the reference prototype strain of the subtype to which the vaccine strain belongs was given in a publication which described some problems with the type A vaccine virus used in Colombia (20) . Examination of the vaccine strain, A 6304, and a number of type A field isolates by the neutralization test against an antiserum prepared from the A 27 subtype reference virus, A Col 1/67, showed them all to be related to that subtype, as had previous examination by the CF test. However, cross neutralization relationships obtained with antisera to the vac cine virus, A 6304, demonstrated significant serological differences (p = <0.05) with two of the field viruses A 7828 and A 7822. One of these viruses A 7828 (V value = 0.16) had been used in a cattle challenge experiment at the Plum Island Laboratory and on the strength of the poor level of protec tion obtained and in the light of apparent vaccine breakdown problems in the field it was concluded that the vaccine was of poor potency and by inference that the Vecol Laboratory, in consultation with Wellcome Foundation Limi ted, lacked technical competence in vaccine manufacture. Some two years later the Control Authority, ICA, changed the vaccine strain to a strain which had a good broad spectrum neutralizing activity against other current A type field strains.
6.
The rationale for making the 'r' value rather than the 'R' value the basis for vaccine strain selection is that we are interested only in how well an antiserum produced against the vaccine strain will neutralize the field virus. The reciprocal relationship is of interest only for classification purposes. A 'r' value based on the neutralization test is capable of offering reasonably precise estimation of the degree of cross-protection that can be expected, within the limits of precision of the V value.
Numerous authors agree that there is good correlation between serum neutralizing antibody titre (SNT) and protection from challenge. Our expe rience over the years has shown that this correlation also holds true when the challenge virus is heterologous.
The relationship takes the form of a sigmoid curve which can be transpo sed to a linear regression by use of Probits, and from such a regression the SNT which equates with 50% protection (PA 50 ) can be estimated. Various authors agree that the PA 50 value is a characteristic of each virus strain.
Another quantifiable relationship of the SNT is that of SNT versus log antigen dose. Based on accumulated data from over 90 antigen extinction point potency tests in cattle we found a pooled mean slope for the regression of log serum titre versus log antigen dose of 0.5 and this has been used to form the basis of a quantitative potency test (16) . We may deduce from this that, if two different batches of vaccine produced mean homologous SNT values in groups of vaccinated cattle which were 0.5 log SNT apart, it is to be expected that the two vaccines will be 1.0 log (i.e. ten-fold) different in potency. Application of this concept would suggest equally that, if a group of vaccinated cattle gave a mean SNT against a heterologous virus which was 0.5 log SNT lower than that to the homologous virus and if the PA 50 values for the two viruses were the same, it is probable that the vaccine would give on average a 1.0 log (i.e. ten-fold) lower potency value against the heterolo gous virus than it would give to the homologous virus.
The differential value (A) between the homologous and heterologous titre is used to calculate the 'r' value.
, , SNT against heterologous (field) virus Thus, r = SNT against homologous (vaccine) virus log 'r' = log heterologous SNT -log homologous SNT 1 and V = antilog A Figure 1 shows the regression slope of 0.5 for log serum titre versus log antigen dose, plotting either A SNT or 'r' value on the Y axis.
FIG. 1 Correlation of cross neutralization and probable cross protection
Using such a regression it is possible to anticipate the likely reduction in potency that will be produced by challenge with a virus which is heterologous to the vaccine virus. Thus a A value of 0.3 (= r value of 0.5) would be expec ted to give rise to a 4-fold reduction in potency. From the error value for an antigen extinction point test in cattle given by Pay and Parker (1977) it can be calculated that a one-sided 95% confidence interval of a PD 50 value is just under three-fold. Thus a vaccine with a true potency value of 18 PD 50 would have approximately only a 5% chance of failing to achieve the 6 PD 50 passmark against an homologous challenge, but would have a greater than 50% chance of failing against challenge with a heterologous virus with a true 'r' value of 0.5.
A value for the regression slope of percentage protection in cattle (Probit) versus log antigen dose of 2.0 has been given (16) . By combining this regres sion slope value of 0.5 with the regression slope value of SNT versus log anti gen dose of 2.0, a theoretical regression slope of 4.0 for percentage protec tion versus SNT can be obtained. Figure 2 shows a graphic representation of the two regressions superimpo sed by plotting both log antigen dose (in PD 50 values) and the corresponding log serum titre together on the X axis. The values shown are for an FMD virus strain with a log SNT PD 50 value of 1.3, and it follows that a group of cattle with a mean log SNT of 1.8 would be expected to show an Estimated Percentage Protection level of 98% (Probit 7.0) and this in turn would equate with an antigen dose of 10 PD 50 .
The basic concepts involved in this method, which has been employed in the Wellcome Laboratory for some years, are very similar in principle to those developed independently by workers at the Pan American Foot and Mouth Disease Centre (8) based on the mouse serum protection index test.
III. -SEROLOGICAL VARIATION AFFECTING EITHER THE VACCINE VIRUS OR THE CHALLENGE VIRUS FOR POTENCY TESTING
Using the criteria we have described for the interpretation of serological data, I will present examples of each sort of variation.
Vaccine virus variation.
In an earlier publication (14) I described how an O1 vaccine strain, O Pacheco, had undergone an antigenic drift, possibly associated with a dele tion of an antigenic determinant. Earlier studies at the World Reference Laboratory had shown O1 Pacheco and O1 Swiss 1/66 to be identical. However, challenge with the O1 Swiss 1/66 virus yielded a very low potency value (0.2 PD 50 ). SNT values against the challenge virus were correspon dingly low, whereas SNT values against the vaccine virus were very high and a high potency would have been anticipated if the challenge had been homo logous to the vaccine virus. Retrospectively, it was shown that the vaccine virus had an SNT 'r' value of 0.14 against the O1 Swiss 1/66 challenge virus. Although my first example cannot be considered to be a clear case of virus variation, it does emphasize the dangers of assuming that virus samples bearing the same name and with passage histories indicating the same origin are necessarily identical. Table I shows that an A Pando vaccine in a first potency test gave a potency of only 2.8 PD 50 against an A Pando challenge virus. This virus was, however, subsequently shown, both by CF tests and neutralization tests, to be closely related to the A 5 subtype and to be significantly different from the A Pando vaccine strain or the A Pando (A 30 ) prototype virus. A second potency test carried out with a cattle challenge virus prepared from the vaccine virus gave a potency of >112 PD 50 , which agrees closely with estimated potency based on homologous antibody in the first test [48 (19-120)1. From the V value of 0.2 calculated from the mean titres of the homologous and heterolo gous groups of vaccinated cattle, a difference in potency could be expected of 25-fold (95% limits 5-100), whereas the observed difference in potency was 40-fold. The example of the Colombian type A vaccine virus described in II.5 above is a related problem in so far as it was assumed that as the challenge virus was within the same subtype it was per se homologous. the probability of a good quality vaccine passing a potency test from approxi mately 95% to 5%. Further studies will continue.
One point emerges quite clearly. Even small antigenic differences between vaccine strains and challenge strains, whether the result of laboratory varia tion or not, are of paramount importance to the vaccine manufacturer, for unless good quality vaccines can regularly pass the quality control potency test it is academic to estimate what their performance might have been against other heterologous strains under field conditions. This problem of matching their vaccine virus to the official challenge virus is the greatest pro blem faced by a manufacturer of FMD vaccines at the present time.
IV. -SEROLOGICAL VARIATION IN FIELD VIRUS
1. In the past, when a new FMD virus has appeared in a country, it has seldom been possible to establish unequivocally whether the new virus is a genetic variant of a previously enzootic virus or whether it represents a new introduction from outside. Newer 'finger-printing' techniques may make this task more feasible. However, whether the virus variation occurred in situ or elsewhere is of interest to the epidemiologist but is largely academic for the vaccine manufacturer. His concern is how well will existing vaccine strains protect against the new virus, and in the past there has been much confused thinking as to the best way of anticipating this. As I have already mentioned, there has been the important problem of how to best interpretate serological data, but there has also been a major problem arising from the fact that only a very limited understanding has existed in general of what a good quality FMD vaccine was capable of achieving under some typical field conditions. Hence, before going further it may be of value to examine some typical res ponses to the recommended regimen. This consists of a primary course of two inoculations with an interval of two to four weeks between them and revaccination at four to 12 months, depending upon the epizootiological cir cumstances.
In passing, it should be noted that FMD vaccine is probably unique among major pharmaceutical or biological products in that it is seldom used in the manner recommended by the manufacturer. Figure 3 shows serum neutralizing antibody responses obtained using such a regimen, under field conditions in Kenya, with a monovalent type SAT 2 vaccine and the type A component in a quadrivalent vaccine (1) . To assist in their interpretation we have transformed them into estimated percentage pro tection values against a fully homologous virus using the regression estimates previously described and assuming an average PA 50 value of 1.3. Figure 4 presents these as a fairly simplistic schematic model depicting herd immunity levels, which is intended to illustrate only some basic principles and does not pretend to be capable of precise interpretation. In constructing the model it has been assumed, for instance, that the correlation of serum antibody titre and protection is the same at say six months after vaccination as it is at 3 to 4 weeks, and also that the level of immunity required to give protection against an average field challenge is similar to that required to withstand a heavy laboratory challenge.
Unlike many other infectious diseases, FMD appears to require the main tenance of critical serum neutralizing antibody levels to ensure protection. The incubation time for FMD is usually so short that the post-infection anamnestic antibody responses in a primed individual, that are recognized as being important in other diseases, can play little part in establishing a protec tive level of immunity.
In situations where a herd has a high risk of exposure to infection throug hout the year, it is probable that protection levels of 95% or more may be required if the disease is to be kept out of the herd. To achieve this, even against a fully homologous virus, a primary course followed by revaccination at four-monthly intervals is probably necessary. Revaccination at sixmonthly intervals will maintain protection levels above the level of 70%, which is accepted as the approximate level of herd immunity which will pre vent an epizootic spread of infection should the disease occur.
Let us now, however, examine the effect on our protection model of an exposure to a field virus which shows a moderate degree of serological varia tion from the vaccine virus. For the purposes of the calculations involved we have assumed that the virus has a true V value of 0.4. The reduction in the effective heterologous antibody level after the second dose of the primary course of vaccination is such that, although it may still be sufficient to pro duce an initial herd immunity level of around 99%, this level falls off more rapidly than that of the homologous immunity. It follows that four-monthly vaccination may not maintain the herd immunity level above 95% and may, therefore, fail to keep the disease out of individual herds which have a high risk of infection throughout the year. Four-monthly vaccination is indeed necessary to maintain herd immunity above the 70% protection level.
It should be stressed that in countries where FMD is enzootic and detailed field surveillance studies are regularly carried out, as for example in Kenya, it is usual to find that a proportion of field isolates will show antigenic diffe rences at least as large as that depicted in this model.
If we now examine the model when the field virus shows a large antigenic difference, say, an 'r' value of 0.1, we find that four-monthly vaccination will not maintain herd immunity levels above the 70% level throughout the year. Consequently, herds exposed to infection two to four months after vac cination may show high morbidity rates and if no other steps are taken it is likely that epizootic spread will occur. However, if such herds around a pri mary focus are immediately revaccinated their level of herd immunity may be raised above the 70% level for a period of a few weeks. Such a level of immu nity if coupled to rigorous zoosanitary measures, such as slaughter and/or total restriction of animal movement, may be sufficient to bring an epizootic under control and to stop the 'brush fire' type of spread of infection.
If one excludes the A 22 epizootic, where the degree of antigen difference with other type A subtypes was of the order of 'r' = 0.01, in nearly every other epizootic caused by a new subtype it has been possible to control the disease in the short term by the revaccination of cattle with the existing subtype vaccine provided appropriate zoosanitary measures were also adop ted. However, if the new subtype displaces the previous virus and becomes enzootic, it may well be necessary to incorporate the new subtype in the vac cine to control the disease in the long term. Sometimes, however, a variant virus will cause a primary focus but fails to establish itself and disappears. It is also interesting in this aspect to note that the antigenic changes in the field do not necessarily follow a path of continuous difference. Quite often recently isolated viruses will show a greater antigenic relationship with subty pes first isolated ten or twenty years previously than they do to viruses isola ted locally in the previous few years. The philosophy that was commonly preached until a few years ago, and indeed was standard practice in some countries, that vaccines should always contain the most recently isolated viru ses is fortunately vanishing. The Pan American Centre has been largely ins trumental in promoting a new philosophy in South America that even in con trolling a highly labile serotype, such as type A, it is better to retain a good broad spectrum virus strain like A 24 Cruzeiro as the baseline antigen and to add to or subtract from it a second A subtype virus as and when required to meet a changing field situation. The baseline serotype antigen should not be replaced in any event until the new candidates strain has been fully characte rised.
Experience over the years has shown that frequent changing of the stock vaccine strain was either often unnecessary or, if potentially of value, by the time the decision to change had been made and effected it was often too late and the field virus situation had changed yet again. In such conditions one was closing a succession of stable doors after a succession of horses had gone.
2.
To conclude, I propose to select three examples from the relatively few publications which give details of cross challenge experiments in vaccinated cattle and also give both homologous and heterologous neutralizing antibody titres. From these I hope to show that the estimated percentage protection values that can be obtained by use of the regressions I have previously descri bed agree in most cases very closely with observed protection values obtained against virus challenge and that the models we have constructed have some validity.
One such publication by Hyslop and colleagues, 1963, is of considerable interest as it compares three type SAT 1 vaccines, one prepared from the RV 11 strain and two prepared from the SA 13/61 strain, in full cross protec tion challenge tests involving more than 120 cattle.
The 'R' value by CF test between these two viruses is 41% and from the serum neutralization test titres 'r' values of 0.21 and 0.14 and an 'R' value of 17% can be calculated. Table II presents With both vaccine strains the agreement between the Estimated Percen tage Protection level against either homologous or heterologous challenge is very close to the observed challenge results. The heterologous results were less clear cut than they might have been due to a number of animals which showed partial protection.
An early experiment which emphasized to me the value of the neutraliza tion test was that reported by myself and Bracewell (15) in which we compa red the immunity produced in cattle by several different vaccination regimens with live modified vaccines against challenge with the A 22 subtype virus. Table III summarized the data and gives the pre-challenge mean serum titres to the homologous A 10 Kemron vaccine strain and to the heterologous A 22 Iraq 24/66 virus. Again, the agreement between predicted and observed levels of protection to the heterologous challenge is good, and quite clearly the neu tralization test data detected the improved level of protection that was obtai ned by boosting the type A Kemron monovalent response with a quadrivalent vaccine also containing type O1, SAT 1 and SAT 2 strains. In the discussion we drew attention to earlier reports which showed that revaccination with a heterologous subtype vaccine could not only give anamnestic levels of anti body response against both the primary and secondary antigens, but could also give enhanced titres against other subtype antigens. We concluded that it seemed probable that in this experiment one or more of the type 01, SAT 1 or SAT 2 antigens had contributed synergistically with the A Kemron antigen to broaden its antigenic spectrum. Apart from the work of Cottral (1972) which showed that significant degrees of cross-neutralization could be obtai ned between strains of different subtypes, no other publications appear to have looked for similarity in the antigen determinants provoking neutralizing antibodies possessed by strains from different serotypes.
The third and last example is taken from a study of the A Morocco 5/77 virus (21) . Table IV Protection levels are likely to give to challenge data. However, in the absence of previous challenge data on which to base a PA 50 estimate, we would use a PA 50 value of 1.5 as this will tend to underestimate the protection level more frequently than it will overestimate it in our experience. However, it must be stressed that for a PA 50 value to be meaningful it must be based on the serum assay system used in the investigation laboratory.
CONCLUSIONS
The present position in relation to the four problem areas discussed may be summarized as follows :
The greatest problem faced by manufacturers at the present time is the matching of their vaccine strain to the official challenge virus strain, as even small antigenic differences can have a profound effect on potency test assays. 4 . New antigenic variants in the field can usually be brought under control by the appropriate tactical use of existing vaccine strains providing that supporting effective zoosanitary procedures are adopted. Existing strains should not be replaced until a full characterization of the new candidate vaccine strain has been made and the demand for it is clear and unequivocal. Local epizootiological factors, however, may require that baseline serotype antigens are augmented by the introduction of second subtype strains in the vaccine from time to time. 
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